Drug Profile
Retinal pigment epithelial cell replacement therapy - Genentech/Lineage Cell Therapeutics/Roche
Alternative Names: OpRegen; OpRegen-Plus; OpRegen® RPE cells; Retinal pigment epithelium transplant therapy; RG-6501; Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE CellsLatest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator Cell Cure Neurosciences
- Developer Cell Cure Neurosciences; Lineage Cell Therapeutics
- Class Cell therapies; Pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Dry age-related macular degeneration; Dry macular degeneration
Most Recent Events
- 11 Oct 2023 Lineage Cell Therapeutics receives patent protection for proprietary manufacturing and differentiation process for retinal pigmented epithelial cells in USA
- 05 Oct 2023 Efficacy data from a phase I/IIa trial in Dry age related macular degeneration released by Lineage Cell Therapeutics
- 21 Jun 2023 Roche plans to file regulatory application for Dry macular degeneration, in or after 2026 (Roche pipeline, June 2023)